Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151793 | 0.84 | LMNA (0.47) | ESR1LMNAADRA1ACYP1A2PGR | |
| SCHEMBL1151780 | 0.84 | LMNA (0.47) | ESR1LMNAADRA1ACYP1A2PGR | |
| SCHEMBL1152470 | 0.82 | LMNA (0.42) | ESR1LMNAADRA1ACYP1A2PGR | |
| SCHEMBL13847317 | 0.80 | TDP1 (0.46) | CYP3A4CYP2D6SLC6A2SLC6A3TDP1 | |
| SCHEMBL25079595 | 0.77 | ESR1 (0.60) | ESR1LMNAADRA1ACYP1A2PGR | |
| SCHEMBL11205024 | 0.77 | LMNA (0.42) | ESR1LMNAADRA1ACYP1A2PGR | |
| SCHEMBL17915614 | 0.77 | ALDH1A1 (0.50) | LMNAALDH1A1 | |
| SCHEMBL10774365 | 0.76 | ESR1 (0.48) | ESR1LMNAADRA1ACYP1A2PGR | |
| SCHEMBL17995329 | 0.76 | IDO1 (0.56) | ESR1LMNACYP3A4MAPTALOX15 | |
| SCHEMBL503028 | 0.76 | IDO1 (0.56) | ESR1LMNACYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | claimed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885LMNA 156/4885ADRA1A 2046/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885LMNA 156/4885ADRA1A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.